Overview

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

This is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic leukemia.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

The First Affiliated Hospital of Soochow University

Collaborator:

Fundamenta Therapeutics, Ltd.

Treatments:

Cyclophosphamide
fludarabine
olverembatinib